Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Cerevel starts dosing volunteers in phase I study of CVL-936

Jan. 31, 2020

Snake venom organoid gives toxin insights

Jan. 30, 2020

Idorsia Pharmaceuticals discovers OX1/OX2 receptor antagonists

Jan. 29, 2020

Results from GLP preclinical study of AAV8-hCocH gene therapy

Jan. 22, 2020

Cobra genome may yield new antivenoms, venom-based drugs

Jan. 8, 2020

Opiant signs letter of intent with NCATS to collaborate on OPNT-004 development

Jan. 3, 2020

Trial to evaluate Trevena's TRV-734 for opioid use disorder

Dec. 24, 2019

Embera NeuroTherapeutics receives funding to advance EMB-001 into phase II studies

Dec. 20, 2019

Indivior selects CRO to conduct phase I study of INDV-2000

Dec. 10, 2019

Adamis Pharmaceuticals receives a complete response letter regarding Zimhi

Nov. 26, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...